What Omeros Corporation’s OncotoX-AML study reveals about mutation-agnostic AML therapies
Omeros Corporation advances OncotoX-AML after primate data. Explore what this means for AML therapy, risks ahead, and why clinicians are watching closely.
Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA
FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.